What is the future of medtech in 2018?

Patents

“Patents have been seen as more vulnerable to attack on various grounds over the past several years. There has been some backlash against non-practicing entities (“patent trolls”). Newer forums such as inter partes reviews (IPRs) have made it easier and less expensive to challenge issued patents. Also, recent Supreme Court decisions such as Alice v. CLS Bank have made it more challenging to patent software – and this includes medical software. Mayo v. Prometheus has made it more difficult to patent medical diagnostics. Yet another Supreme Court decision, TC Heartland, has limited the venue for patent lawsuits, moving cases out of the Eastern District of Texas – a court that is often said to be very favorable to patent plaintiffs.

However, the pendulum may be swinging back the other way. There has been a recent trend at the Patent Appeals Board to strike down fewer patents. The pending Oil States case before the Supreme Court challenging the constitutionality of IPRs could possibly wipe out IPRs entirely, making it more difficult and costly to challenge patents. Also, the proposed STRONGER Patents Act has additional provisions that make challenging patents procedurally more difficult. This could possibly spur innovation further, as medical device companies gain additional confidence in the strength and value of patents.” —Bryan Wahl, partner at Knobbe Martens

Next>>

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW